RION is at the forefront of regenerative medicine, focusing on the innovative use of exosomes derived from platelets to promote tissue regeneration. The company has developed a unique product known as Purified Exosome Product (PEP™), which is isolated from platelets and contains trillions of regenerative exosomes. This product is the result of RION's proprietary manufacturing process, which not only allows for the mass production of exosomes but also addresses scalability challenges in the industry. PEP™ is designed to be versatile, with the capability to regenerate various types of tissues, including skin, heart, muscle, and nerve, and can be administered through multiple routes such as topical, intravenous, and nebulizer applications.

In addition to its regenerative capabilities, RION is advancing the field of drug delivery through its next-generation exosome technology. This platform enables the encapsulation of therapeutic payloads, such as mRNA, DNA, and small molecules, within the exosomes, enhancing their bioavailability and targeting efficiency. The protective lipid bilayer of PEP™ not only improves the distribution of the therapeutic cargo but also reduces systemic toxicities, making it a promising vehicle for delivering a wide range of treatments. RION's commitment to harnessing the regenerative properties of exosomes positions it as a leader in transforming the landscape of regenerative medicine.

United States

Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics that are clinically impactful, accessible, and practical for any patient, anywhere. Rion has developed Purified Exosome Product (PEP), an innovative biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine.

Rion

Company Details